Skip to Content

Additional Content In This Section

CANTOS

CANTOS

Objective

Status
Enrollment complete

Condition
Atherosclerosis

Description

A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post myocardial infarction patients with elevated hsCRP

  • Written informed consent
  • Male, or Female of non-child-bearing potential
  • Age ≥ 18 years.
  • Spontaneous MI at least 30 days before randomization.
  • hsCRP ≥ 2 mg/L

Purpose
The purpose of this trial is to test the hypothesis that canakinumab treatment of persons with myocardial infarction (MI) at least one month prior to study entry and elevated hsCRP will prevent recurrent cardiovascular events. 

Phase
III

Key Inclusion Criteria

  • Written informed consent
  • Male, or Female of non-child-bearing potential
  • Age ≥ 18 years.
  • Spontaneous MI at least 30 days before randomization.
  • hsCRP ≥ 2 mg/L

Key Exclusion Criteria

  • Pregnant or nursing (lactating) women
  • Women of child-bearing potential
  • Any of the following concomitant diseases
  • Planned coronary revascularization (PCI or CABG)
  • Major non-cardiac surgical or endoscopic procedure within past 6       months
  • Multi-vessel CABG surgery within the past 3 years
  • Symptomatic patients with Class IV heart failure (HF) (New York        Heart Association [NYHA].
  • Uncontrolled hypertension
  • Uncontrolled diabetes
  • History or evidence of active tuberculosis (TB) infection

Other protocol-defined inclusion/exclusion criteria may apply

ClinicalTrials.gov Identifier

NCT01327846

IRB Protocol Number
ACZ885M2301
Principal Investigator(s)
Rabeea Aboufakher, MD

Clinical Trial Categories

  • Cardiology
Sponsor(s)
Novartis
Contact
Dianne Vold, LPN CCRC at 701-780-1559
or dvold@altru.org